Welcome to our dedicated page for Incyte SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Incyte’s latest 10-K means sifting through pages of clinical-trial data, FDA milestones, and royalty tables—details that can obscure crucial signals like how much Jakafi revenue offsets soaring R&D costs. If finding Incyte insider trading Form 4 transactions before a pivotal read-out feels daunting, you’re not alone.
Stock Titan’s AI reads every Incyte quarterly earnings report 10-Q filing, 8-K material events explained, and the full Incyte annual report 10-K simplified so you don’t have to. Our platform delivers real-time alerts the moment an Incyte Form 4 insider transactions real-time notice posts to EDGAR, then translates legal jargon into plain English. Need a quick brief on trial spend vs. cash reserves? Our AI-powered summaries surface it in one click, making understanding Incyte SEC documents with AI part of your routine.
Use the filing types below to answer the questions professionals ask every quarter:
- 10-Q: Track segment revenue, pipeline spend, and compare results with our Incyte earnings report filing analysis.
- 10-K: Review patent cliffs, market-size assumptions, and risk factors—Incyte SEC filings explained simply.
- Form 4: Monitor Incyte executive stock transactions Form 4 for buying or selling patterns.
- DEF 14A: See the Incyte proxy statement executive compensation section without hunting through tables.
- 8-K: Get Incyte 8-K material events explained within minutes of release.
Whether you’re gauging partnership royalty streams or confirming cash runway, Stock Titan turns dense biotech disclosures into actionable knowledge—before the market reacts.
On 26 June 2025, Incyte Corporation (NASDAQ: INCY) filed a Form 4 reporting an insider transaction by Chief Executive Officer and Director William Meury. The filing discloses a grant of 110,630 employee stock options with an exercise price of $70.81 per share. The options vest 25 % after one year, with the remaining 75 % vesting in equal monthly installments over the subsequent three years, and expire on 25 June 2035. After this grant, Meury beneficially owns 110,630 derivative securities, held directly. No purchases or sales of common stock were reported, and the transaction is classified as "A" (acquisition). The document was signed on 30 June 2025.
FAQ
What is the current stock price of Incyte (INCY)?
What is the market cap of Incyte (INCY)?
